A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer

International Journal of Hyperthermia

Volumn 30, Issue 3, 2014, Pages 171-175

  Inman, Brant A ^a   Stauffer, Paul R ^b   Craciunescu, Oana A ^a   Maccarini, Paolo F ^a   Dewhirst, Mark W ^a   Vujaskovic, Zeljko ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Clinical trial; Hyperthermia; Mitomycin C

Indexed keywords

BCG VACCINE; MITOMYCIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLADDER SPASM; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CHEMICAL CYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIZZINESS; EXTERNAL DEEP PELVIC HYPERTHERMIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FLUSHING; FOLEY BALLOON CATHETER; FOLLOW UP; HEAT INTOLERANCE; HEATING; HEMATURIA; HUMAN; HYPERTENSION; HYPERTHERMIA; LUNG DISEASE; MALE; MYALGIA; NAUSEA; NON MUSCLE INVASIVE BLADDER CANCER; PILOT STUDY; PRURITUS; RASH; SKIN BRUISING; SKIN SWELLING; SUPINE POSITION; TREATMENT OUTCOME; URETHRAL PAIN; URINARY TRACT INFECTION; VAGINITIS; VOMITING; HYPERTHERMIC THERAPY; MIDDLE AGED; PATHOLOGY; PELVIS; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

AGED; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; PELVIS; PILOT PROJECTS; URINARY BLADDER NEOPLASMS;

EID: 84899744608     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2014.882021     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook, 7th ed. New York: Springer, 2010.
3. Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA. Perioperative intravesical chemotherapy in non-muscleinvasive bladder cancer: A systematic review and meta-Analysis. J Natl Compr Canc Netw 2013;11:477-84.
4. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-Analysis of the long-Term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscleinvasive bladder cancer. Eur Urol 2009;56:247-56.
5. Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466-71.
6. Yuan Y, Cheng KS, Craciunescu OI, Stauffer PR, Maccarini PF, Arunachalam K, et al. Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma. Med Phys 2012;39:1170-81.
7. Salahi S, Maccarini PF, Rodrigues DB, Etienne W, Landon CD, Inman BA, et al. Miniature microwave applicator for murine bladder hyperthermia studies. Int J Hyperthermia 2012;28:456-65.
8. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001;17:1-18.
9. Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: A systematic review. Eur Urol 2011;60:81-93.
10. Van Der Zee J, Gonzalez Gonzalez D, Van Rhoon GC, Van Dijk JD, Van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355:1119-25.
11. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, et al. Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604.
12. Van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65-71; discussion 71-2.
13. Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270-6.
14. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18: 695-706.
16. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2013.
17. Sylvester RJ, Van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
18. Witjes JA. Management of BCG failures in superficial bladder cancer: A review. Eur Urol 2006;49:790-7.
19. Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol 2009;182: 70-7.
20. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al. Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance. J Clin Oncol 2010;28:543-8.
21. McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albuminbound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol 2011;186: 448-51.
22. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344-8.
23. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. Valrubicin Study Group. J Urol 2000;163:761-7.
24. Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol 2012;187:1195-9.
25. Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial nonmuscle invasive bladder cancer: A randomised controlled trial. Lancet Oncol 2011;12:871-9.
26. Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-Term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:912-8.